Qiagen Stock Price, News & Analysis

QIAGEN N.V. (NYSE: QGEN) announced it will release its third-quarter 2022 results on November 7 at 22:05 Frankfurt time. A conference call for discussion will occur the following day, November 8, at 15:00 Frankfurt time. Participants can join via a callback registration, phone dial-in, or by accessing an audio webcast. QIAGEN, based in the Netherlands, provides solutions enabling molecular insights from biological samples, supporting over 500,000 customers globally.

IGI Inex Holding has announced its strategic investment in quantumrock, a Munich-based AI and machine learning asset management company. This investment positions IGI with a relevant share based on quantumrock's valuation of €30 million, with options to increase its stake over time. The partnership aims to create innovative investment products that offer loss protection features desired by institutional investors. Quantumrock plans to leverage IGI’s precious stone holdings to develop unique investment strategies, enhancing their asset-backed investment product offerings.

QIAGEN N.V. (NYSE: QGEN) has expanded its NeuMoDx assay menu with new CE-IVD certified tests for Epstein-Barr virus (EBV) and human herpesvirus 6 (HHV-6), bringing the total to 16 assays. These tests enhance monitoring for immunocompromised organ transplant patients, addressing significant postoperative risks. The company is also developing a multiplex assay for monkeypox and a new dual-target SARS-CoV-2 test, aimed at improving respiratory disease diagnostics. QIAGEN's automated solutions streamline workflows and improve lab efficiency.

QIAGEN has signed a collaboration agreement with Neuron23 to develop a companion diagnostic for a LRRK2 inhibitor aimed at treating Parkinson’s disease. This assay will utilize next-generation sequencing (NGS) technology to identify biomarkers predicting patient responsiveness. The collaboration enhances QIAGEN's NGS testing portfolio, expanding its precision medicine applications into neurology. Neuron23's LRRK2 inhibitor is in late-stage preclinical development, and this partnership is part of QIAGEN's strategy to leverage its expertise in molecular testing to support groundbreaking therapies.

Neuron23 and QIAGEN announced a collaboration on September 14, 2022, to develop the first companion diagnostic for Neuron23’s LRRK2 inhibitor aimed at treating Parkinson’s disease. Under the agreement, QIAGEN will create a clinical trial assay detecting biomarkers that predict patient responsiveness to the drug. This assay will be integrated into a next-generation sequencing workflow, facilitating concurrent submissions for FDA approval of both the diagnostic test and drug application.

The collaboration highlights the potential of precision medicine in neurodegenerative diseases.

QIAGEN has launched the QIAstat-Dx Viral Vesicular Panel RUO, a groundbreaking test to differentiate monkeypox from five other pathogens. This test, utilizing gold-standard PCR technology, is vital for global surveillance as monkeypox cases increase. Currently available for research use only, the panel will support healthcare authorities in the fight against infectious diseases. With over 3,000 QIAstat-Dx devices deployed worldwide, QIAGEN aims to enhance testing capabilities significantly as they prepare for potential clinical applications pending regulatory developments.

QIAGEN (NYSE: QGEN) has announced significant enhancements to its QIAcuity digital PCR (dPCR) systems, including 13 new kits and assays for AAV viral titer and host cell DNA quantification, aimed specifically at biopharma applications. With over 1,000 cumulative placements since launch in late 2020, the updates also feature an upgraded software suite for GMP compliance. These developments are designed to improve efficiency and expand the utility of QIAcuity for biopharma customers, enhancing drug development processes.

QIAGEN N.V. reported Q2 2022 net sales of $516 million, reflecting a 9% decline year-over-year, while adjusted diluted EPS reached $0.51. Despite the downturn in COVID-19 sales by 39% to $92 million, non-COVID sales rose 10% to $423 million. Operating cash flow increased by 33% to $379 million, with raised full-year sales outlook set at least at $2.2 billion. The company maintains a positive trajectory in non-COVID products, projecting continued growth amid economic challenges.